Drug Profile

AD 04 - Advantage Therapeutics

Alternative Names: AD04™; AD04™ - Advantage Therapeutics; Alhydrogel^®

Latest Information Update: 26 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AFFiRiS
Developer ADvantage Therapeutics; AFFiRiS
Class Antidementias
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Alzheimer's disease

Most Recent Events

28 Jul 2024 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2024)
15 May 2024 Adial Pharmaceuticals has patent protection for AD 04 in USA
20 Jun 2023 ADvantage Therapeutics receives Clinical Trial Application (CTA) approval to commence a phase IIb trial for Alzheimer’s disease in Poland, Bulgaria and Slovakia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com